archiveRHPI:PUBLIC-HEALTH

Investing

Novo Nordisk invests $6 bln in Wegovy production, still far below demand -CEO

The logo of Danish drugmaker Novo Nordisk, Copenhagen, Denmark, September 26, 2023. REUTERS/Tom Little/File Photo Acquire Licensing RightsLONDON/COPENHAGEN, Nov 10 (Reuters) - Obesity drug maker Novo Nordisk (NOVOb.CO) said on Friday it will spend $6 billion to boost production in Denmark, although its chief executive warned the industry was far from being able to produce enough weight-loss drugs to meet global demand.Novo Nordisk has had phenomenal success with its anti-obesity drug, Wegovy, but has scrambled to address shortages that have forced it to limit the number of patients.The World Health...